Background—Published rates of coronary restenosis have fallen below 10% in drug-eluting stent trials. Early evaluations of new stents have used continuous end points that are presumed surrogates for restenosis, but the generalizability and power of such end points have not been examined systematically. Methods and Results—We examined the relationship between incremental changes in observed late...

The purpose of intracoronary brachytherapy is to reduce the incidence of lesion recurrence (restenosis) after percutaneous coronary intervention. Its rationale is based on the concept that restenosis is a process of benign tissue proliferation and that locally applied radiation can prevent or attenuate the magnitude of this response. After encouraging results from animal models,1,2 small observ...

The current treatment for coronary restenosis following balloon angioplasty involves the use of a mechanical or a drug-eluting stent. Despite the high usage of commercially-available drug-eluting stents in the cardiac field, there are a number of limitations. This review will present the background ofrestenosis, go briefly into the molecular and cellular mechanisms of restenosis, the use of mec...

Percutaneous Transluminal Coronary Angioplasty To the Editor: Manegold et al1 compared the incidence of prior cytomegalovirus (CMV) infection and the risk of restenosis after percutaneous transluminal coronary angioplasty (PTCA) in 92 consecutive patients. A total of 65% of these patients were positive for IgG CMV antibodies. At 6 months, angiographic restenosis was similar in CMV-positive and ...

In a recent editorial, John S. Douglas Jr. elegantly describes the issue of drug-eluting stent (DES) restenosis (1). This editorial refers to the RIBS (Restenosis Intra-Stent: Balloon Angioplasty Versus Drug-Eluting Stent) III trial, a study whose aim was to compare different strategies for the treatment of DES restenosis, and whose findings revealed that choosing a different DES provides bette...

OBJECTIVES (a) To assess the echocardiographic incidence of restenosis after successful balloon dilatation of the mitral valve at a mid-term follow up of one year among a population of predominantly United Kingdom patients. (b) To identify any factors, assessed before or during dilatation, which may predict the development of restenosis. DESIGN Successful dilatation of the mitral valve was de...

Percutaneous coronary intervention (PCI) is one of the main components in treatment artery disease (CAD) and especially its acute forms. Nevertheless, restenosis stented arteries, which significantly worsens course CAD, remains a significant clinical problem this technology. Prevention complication requires modern understanding complex pathogenetic mechanisms restenosis. Based on literature dat...

A retrospective study from two centers March 2017 to January 2020. For 97 patients who had undergone transcarotid artery revascularization (TCAR), the average duplex ultrasound (DU) findings at 12 months after procedure (36% of reached this time point date) were a peak systolic velocity (PSV) 167 ± 153 cm/s, end-diastolic (EDV) 51 55 and internal carotid artery/common (ICA/CCA) ratio 2.3 1.9. F...

OBJECTIVES We analyzed the effects of vascular brachytherapy (VBT) on ostial in-stent restenosis (ISR). BACKGROUND In-stent restenosis has a high recurrence rate after percutaneous reintervention. The recurrence rate of ostial ISR lesions and the impact of VBT remain unknown. METHODS We evaluated 133 patients with native coronary ostial ISR from a pooled database of 990 patients enrolled in...

OBJECTIVES To define velocity criteria by ultrasonography for the detection of hemodynamically significant (>60%) renal artery in-stent restenosis (ISR). BACKGROUND The restenosis rate after renal artery stenting ranges between 10% and 20%. While duplex ultrasound criteria have been validated for native renal artery stenosis, there are no uniformly accepted validated criteria for stented rena...